Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
- BYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor or after receiving up to one additional line of therapy[1]
- SOLAR-1 is the first Phase III breast cancer trial to demonstrate potential viability of using liquid biopsy to select patients for targeted treatment[1]
- Novartis continues to invest in flexible genomic profiling solutions to identify the approximately 40% of HR+ advanced breast cancer patients with a PIK3CA mutation who may benefit from targeted therapy[2]
# # # Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.com
Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Julie Masow Novartis Oncology Media Relations +1 862 579 8456 (mobile) julie.masow@novartis.com |